Arthritis Research & Therapy

official impact factor 4.36

Commentary

p53 in rheumatoid arthritis: friend or foe?

Ulf Müller-Ladner 1 and Kusuki Nishioka2

Author Affiliations

1 University of Regensburg, Regensburg, Germany

2 St Marianna university, Kawasaki, Japan

For all author emails, please log on.

Arthritis Res 2000, 2:175-178 doi:10.1186/ar84

Published: 31 March 2000

Abstract

The knowledge of transcription factors and proto-oncogenes has influenced the understanding of cell regulation, cell

cycle, and apoptotic cell death in rheumatoid arthritis (RA) synovium. In addition, the development of normal synovial fibroblasts into transformed-appearing aggressive synovial fibroblasts may be triggered by the lack of antiproliferative factors, such as p53, p53-associated molecules, other tumor suppressors, as well as by upregulation of anti-apoptotic genes. Therefore, data derived from experiments such as those performed by Tak and colleagues in this issue of Arthritis Research not only enrich the intensive discussion addressing the impact of p53 on RA pathophysiology, they also may facilitate development of novel therapeutic approaches including p53-targeted gene therapy.

Keywords:
gene therapy; MDM2; p53; p73; rheumatoid arthritis